The diversity of soft tissue tumours with EWSR1 gene rearrangements: A review

Histopathology

Volumn 64, Issue 1, 2014, Pages 134-150

  Fisher, Cyril ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

EWSR1; Molecular diagnosis; Sarcoma; Soft tissue tumour

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CD99 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKERATIN; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MELAN A; MONOCLONAL ANTIBODY D2-40; MONOCLONAL ANTIBODY HMB 45; MUCIN 4; NUCLEAR RECEPTOR NR4A3; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN S 100; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR YY1;

ACTIVATING TRANSCRIPTION FACTOR 1 GENE; ANGIOSARCOMA; CELL STRUCTURE; CHONDROSARCOMA; CLEAR CELL SARCOMA; CYCLIC AMP RESPONSIVE ELEMENT BINDING GENE; DERMATOFIBROMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; EPITHELIOID CELL; EWING SARCOMA; EWSR1 GENE; FIBROSARCOMA; FLI1 GENE; FUSION GENE; GENE; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GIANT CELL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE GENE 153; HISTIOCYTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MYOEPITHELIOMA; MYXOSARCOMA; NUCLEAR RECEPTOR NR4A3 GENE; OCTAMER TRANSCRIPTION FACTOR 4 GENE; PRIORITY JOURNAL; REVIEW; SMARCA5 GENE; SOFT TISSUE TUMOR; SPINDLE CELL; STROMA; TRANSCRIPTION FACTOR ER81 GENE; TRANSCRIPTION FACTOR ERG GENE; TRANSCRIPTION FACTOR NFATC2 GENE; TRANSCRIPTION FACTOR PBX1 GENE; TRANSCRIPTION FACTOR SP3 GENE; TRANSCRIPTION FACTOR YY1 GENE; WT1 GENE; ZSG GENE;

EWSR1; MOLECULAR DIAGNOSIS; SARCOMA; SOFT TISSUE TUMOUR;

CALMODULIN-BINDING PROTEINS; GENE REARRANGEMENT; HUMANS; RNA-BINDING PROTEINS; SARCOMA;

EID: 84889648566     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12269     Document Type: Review

References (214)

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007; 7; 233-245.
2. Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat. Rev. Genet. 2010; 11; 819-829.
3. Soutoglou E, Misteli T. On the contribution of spatial genome organization to cancerous chromosome translocations. J. Natl. Cancer Inst. Monogr. 2008; 39; 16-19.
4. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20; 5747-5754.
5. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994; 54; 2837-2840.
6. Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc. Natl Acad. Sci. USA 1995; 92; 1028-1032.
7. Antonescu CR, Gerald WL, Magid MS, Ladanyi M. Molecular variants of the EWS-WT1 gene fusion in desmoplastic small round cell tumor. Diagn. Mol. Pathol. 1998; 7; 24-28.
8. Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12; 489-494.
9. Dal Cin P, Sciot R, Panagopoulos I et al. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features. J. Pathol. 1997; 182; 437-441.
10. Hosaka T, Nakashima Y, Kusuzaki K et al. A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. J. Mol. Diagn. 2002; 4; 164-171.
11. Matsui Y, Ueda T, Kubo T et al. A novel type of EWS-CHOP fusion gene in myxoid liposarcoma. Biochem. Biophys. Res. Commun. 2006; 348; 437-440.
12. Suzuki K, Matsui Y, Hashimoto N et al. Variation in myxoid liposarcoma: clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma. Oncol. Lett. 2012; 3; 293-296.
13. Clark J, Benjamin H, Gill S et al. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene 1996; 12; 229-235.
14. Labelle Y, Zucman J, Stenman G et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum. Mol. Genet. 1995; 4; 221-2226.
15. Sciot R, Dal Cin P, Fletcher C et al. t(9;22)(q22-31;q11-12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Mod. Pathol. 1995; 8; 765-768.
16. Stenman G, Andersson H, Mandahl N, Meiskindblom JM, Kindblom LG. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int. J. Cancer 1995; 62; 398-402.
17. Attwooll C, Tariq M, Harris M, Coyne JD, Telford N, Varley JM. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene 1999; 18; 7599-7601.
18. Panagopoulos I, Mencinger M, Dietrich CU et al. Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11). Oncogene 1999; 18; 7594-7598.
19. Sjogren H, Meis-Kindblom J, Kindblom LG, Aman P, Stenman G. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res. 1999; 59; 5064-5067.
20. Sjogren H, Wedell B, Meis-Kindblom JM, Kindblom LG, Stenman G. Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res. 2000; 60; 6832-6835.
21. Hallor KH, Mertens F, Jin Y et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosom. Cancer 2005; 44; 97-102.
22. Chen G, Folpe AL, Colby TV et al. Angiomatoid fibrous histiocytoma: unusual sites and unusual morphology. Mod. Pathol. 2011; 24; 1560-1570.
23. Rossi S, Szuhai K, Ijszenga M et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin. Cancer Res. 2007; 13; 7322-7328.
24. Antonescu CR, Dal Cin P, Nafa K et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosom. Cancer 2007; 46; 1051-1060.
25. Zucman J, Delattre O, Desmaze C et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat. Genet. 1993; 4; 341-345.
26. Hisaoka M, Ishida T, Kuo TT et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am. J. Surg. Pathol. 2008; 32; 452-460.
27. Wang WL, Mayordomo E, Zhang W et al. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod. Pathol. 2009; 22; 1201-1209.
28. Thway K, Nicholson AG, Lawson K et al. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am. J. Surg. Pathol. 2011; 35; 1722-1732.
29. Antonescu CR, Zhang L, Chang NE et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosom. Cancer 2010; 49; 1114-1124.
30. Jo VY, Antonescu CR, Zhang L, Dal Cin P, Hornick JL, Fletcher CD. Cutaneous syncytial myoepithelioma: clinicopathologic characterization in a series of 38 cases. Am. J. Surg. Pathol. 2013; 37; 710-718.
31. Lau PP, Lui PC, Lau GT, Yau DT, Cheung ET, Chan JK. EWSR1-CREB3L1 Gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am. J. Surg. Pathol. 2013; 37; 734-738.
32. Doyle LA, Wang WL, Dal Cin P et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am. J. Surg. Pathol. 2012; 36; 1444-1451.
33. Panagopoulos I, Thorsen J, Gorunova L et al. RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12). Genes Chromosom. Cancer 2013; 52; 733-740.
34. Antonescu CR, Katabi N, Zhang L et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosom. Cancer 2011; 50; 559-570.
35. Shah AA, LeGallo RD, van Zante A et al. EWSR1 genetic rearrangements in salivary gland tumors: a specific and very common feature of hyalinizing clear cell carcinoma. Am. J. Surg. Pathol. 2013; 37; 571-578.
36. Moller E, Stenman G, Mandahl N et al. POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. J. Pathol. 2008; 215; 78-86.
37. Plougastel B, Zucman J, Peter M, Thomas G, Delattre O. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 1993; 18; 609-615.
38. Bovee JV, Devilee P, Cornelisse CJ, Schuuring E, Hogendoorn PC. Identification of an EWS-pseudogene using translocation detection by RT-PCR in Ewing's sarcoma. Biochem. Biophys. Res. Commun. 1995; 213; 1051-1060.
39. Zakaryan RP, Gehring H. Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. J. Mol. Biol. 2006; 363; 27-38.
40. Azuma M, Embree LJ, Sabaawy H, Hickstein DD. Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. PLoS ONE 2007; 2; e979.
41. Leemann-Zakaryan RP, Pahlich S, Sedda MJ, Quero L, Grossenbacher D, Gehring H. Dynamic subcellular localization of the Ewing sarcoma proto-oncoprotein and its association with and stabilization of microtubules. J. Mol. Biol. 2009; 386; 1-13.
42. Li H, Watford W, Li C et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J. Clin. Invest. 2007; 117; 1314-1323.
43. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 1996; 15; 5022-5031.
44. Delattre O, Zucman J, Plougastel B et al. Gene fusion with ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359; 162-165.
45. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363; 640-644.
46. Morohoshi F, Arai K, Takahashi EI, Tanigami A, Ohki M. Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins. Genomics 1996; 38; 51-57.
47. Stolow DT, Haynes SR. Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation. Nucleic Acids Res. 1995; 23; 835-843.
48. Riggi N, Cironi L, Suva ML, Stamenkovic I. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J. Pathol. 2007; 213; 4-20.
49. Kim J, Pelletier J. Molecular genetics of chromosome translocations involving EWS and related family members. Physiol. Genomics 1999; 1; 127-138.
50. Sandberg A, Bridge J. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma. Cancer Genet. Cytogenet. 2002; 136; 1-9.
51. Sandberg AA, Bridge JA. Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet. Cytogenet. 2000; 123; 1-26.
52. Antonescu CR, Elahi A, Humphrey M et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma. Absence in predominantly myxoid well-differentiated liposarcoma. J. Mol. Diagn. 2000; 2; 132-138.
53. Panagopoulos I, Mertens F, Debiec-Rychter M et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int. J. Cancer 2002; 99; 560-567.
54. Folpe AL, Goldblum JR, Rubin BP et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am. J. Surg. Pathol. 2005; 29; 1025-1033.
55. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43; 2438-2451.
56. Applebaum MA, Worch J, Matthay KK et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011; 117; 3027-3032.
57. Potratz J, Dirksen U, Jurgens H, Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatr. Hematol. Oncol. 2012; 29; 1-11.
58. Bridge JA, Fidler ME, Neff JR et al. Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Am. J. Surg. Pathol. 1999; 23; 159-165.
59. Llombart-Bosch A, Pellin A, Carda C, Noguera R, Navarro S, Peydro-Olaya A. Soft tissue Ewing sarcoma-peripheral primitive neuroectodermal tumor with atypical clear cell pattern shows a new type of EWS-FEV fusion transcript. Diagn. Mol. Pathol. 2000; 9; 137-144.
60. Llombart-Bosch A, Machado I, Navarro S et al. Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch. 2009; 455; 397-411.
61. Yoshida A, Sekine S, Tsuta K, Fukayama M, Furuta K, Tsuda H. NKX 2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am. J. Surg. Pathol. 2012; 36; 993-999.
62. Parham DM, Dias P, Kelly DR, Rutledge JC, Houghton P. Desmin positivity in primitive neuroectodermal tumors of childhood. Am. J. Surg. Pathol. 1992; 16; 483-492.
63. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res. 2009; 69; 7140-7150.
64. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation t(21;22) fuses the EWS gene to another ETS-family transcription factor ERG. Nat. Genet. 1994; 6; 146-151.
65. Maire G, Brown CW, Bayani J et al. Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genet. Cytogenet. 2008; 181; 81-92.
66. Wang WL, Patel NR, Caragea M et al. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod. Pathol. 2012; 25; 1378-1383.
67. Tomlins SA, Palanisamy N, Brenner JC et al. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am. J. Clin. Pathol. 2013; 139; 771-779.
68. Jeon IS, Davis JN, Braun BS et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10; 1229-1234.
69. Kaneko Y, Yoshida K, Handa M et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosom. Cancer 1996; 15; 115-121.
70. Peter M, Couturier J, Pacquement H et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14; 1159-1164.
71. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 1994; 54; 2865-2868.
72. Berg T, Kalsaas AH, Buechner J, Busund LT. Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript. Cancer Genet. Cytogenet. 2009; 194; 53-57.
73. Ng TL, O'Sullivan MJ, Pallen CJ et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J. Mol. Diagn. 2007; 9; 459-463.
74. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PC. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin. Cancer Res. 2009; 15; 2259-2268.
75. Yamaguchi S, Yamazaki Y, Ishikawa Y, Kawaguchi N, Mukai H, Nakamura T. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosom. Cancer 2005; 43; 217-222.
76. Sumegi J, Nishio J, Nelson M, Frayer RW, Perry D, Bridge JA. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Mod. Pathol. 2011; 24; 333-342.
77. Mastrangelo T, Modena P, Tornielli S et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000; 19; 3799-3804.
78. Wang L, Bhargava R, Zheng T et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J. Mol. Diagn. 2007; 9; 498-509.
79. Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC, 2013; 305-310.
80. Shulman SC, Katzenstein H, Bridge J et al. Ewing sarcoma with 7;22 translocation: three new cases and clinicopathological characterization. Fetal Pediatr. Pathol. 2012; 31; 341-348.
81. Italiano A, Sung YS, Zhang L et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosom. Cancer 2012; 51; 207-218.
82. Graham C, Chilton-MacNeill S, Zielenska M, Somers GR. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum. Pathol. 2012; 43; 180-189.
83. Kawamura-Saito M, Yamazaki Y, Kaneko K et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 2006; 15; 2125-2137.
84. Yoshimoto M, Graham C, Chilton-MacNeill S et al. Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. Cancer Genet. Cytogenet. 2009; 195; 1-11.
85. May WA, Lessnick SL, Braun BS et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 1993; 13; 7393-7398.
86. Hahm KB, Cho K, Lee C et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat. Genet. 1999; 23; 222-227.
87. Tirado OM, Mateo-Lozano S, Villar J et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res. 2006; 66; 9937-9947.
88. Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S, Iwamoto Y. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br. J. Cancer 2001; 84; 768-775.
89. Camoes MJ, Paulo P, Ribeiro FR et al. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma. PLoS ONE 2012; 7; e49819.
90. Richter GH, Plehm S, Fasan A et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl Acad. Sci. USA 2009; 106; 5324-5329.
91. Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA. FOXM1 is an oncogenic mediator in Ewing sarcoma. PLoS ONE 2013; 8; e54556.
92. Joo J, Christensen L, Warner K et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 2009; 4; e7608.
93. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009; 28; 4126-4132.
94. Fuchs B, Inwards C, Scully SP, Janknecht R. hTERT is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin. Orthop. 2004; 426; 64-68.
95. Cironi L, Riggi N, Provero P et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS ONE 2008; 3; e2634.
96. Scotlandi K, Manara MC, Serra M et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur. J. Cancer 2011; 47; 1258-1266.
97. Garcia-Aragoncillo E, Carrillo J, Lalli E et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 2008; 27; 6034-6043.
98. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin. Cancer Res. 2004; 10; 1344-1353.
99. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 2004; 24; 7275-7283.
100. Nakatani F, Tanaka K, Sakimura R et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J. Biol. Chem. 2003; 278; 15105-15115.
101. de Alava E, Kawai A, Healey JH et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 1998; 16; 1248-1255.
102. van Doorninck JA, Ji L, Schaub B et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 2010; 28; 1989-1994.
103. Le Deley MC, Delattre O, Schaefer KL et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 2010; 28; 1982-1988.
104. Wang L, Motoi T, Khanin R et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosom. Cancer 2012; 51; 127-139.
105. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round cell tumor. Report of 19 cases of a distinctive type of high grade polyphenotypic malignancy affecting young individuals. Am. J. Surg. Pathol. 1991; 15; 499-513.
106. Cummings OW, Ulbright TM, Young RH, Del Tos AP, Fletcher CD, Hull MT. Desmoplastic small round cell tumors of the paratesticular region. A report of six cases. Am. J. Surg. Pathol. 1997; 21; 219-225.
107. Crisci KL, Greenberg B, Wolfson BJ. Cardiopulmonary and thoracic tumors of childhood. Radiol. Clin. North Am. 1997; 35; 1341.
108. Tison V, Cerasoli S, Morigi F, Ladanyi M, Gerald WL, Rosai J. Intracranial desmoplastic small-cell tumor. Report of a case. Am. J. Surg. Pathol. 1996; 20; 112-117.
109. Ordonez NG. Desmoplastic small round cell tumor: I. A histopathologic study of 39 cases with emphasis on unusual histological patterns. Am. J. Surg. Pathol. 1998; 22; 1303-1313.
110. Sawyer JR, Tryka AF, Lewis JM. A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am. J. Surg. Pathol. 1992; 16; 411-416.
111. Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin. Cancer Biol. 2005; 15; 197-205.
112. Lee SB, Kolquist KA, Nichols K et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat. Genet. 1997; 17; 309-313.
113. Katz RL, Quezado M, Senderowicz AM, Villalba L, Laskin WB, Tsokos M. An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. Hum. Pathol. 1997; 28; 502-509.
114. Thway K, Rockcliffe S, Gonzalez D et al. Utility of sarcoma-specific fusion gene analysis in paraffin-embedded material for routine diagnosis at a specialist centre. J. Clin. Pathol. 2010; 63; 508-512.
115. Alaggio R, Rosolen A, Sartori F et al. Spindle cell tumor with EWS-WT1 transcript and a favorable clinical course: a variant of DSCT, a variant of leiomyosarcoma, or a new entity? Report of 2 pediatric cases. Am. J. Surg. Pathol. 2007; 31; 454-459.
116. Antonescu CR, Elahi A, Healey JH et al. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Clin. Cancer Res. 2000; 6; 2788-2793.
117. Spillane AJ, Fisher C, Thomas JM. Myxoid liposarcoma-the frequency and the natural history of nonpulmonary soft tissue metastases. Ann. Surg. Oncol. 1999; 6; 389-394.
118. Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities: a clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am. J. Surg. Pathol. 1996; 20; 171-180.
119. Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996; 77; 1450-1458.
120. Fritchie KJ, Goldblum JR, Tubbs RR et al. The expanded histologic spectrum of myxoid liposarcoma with an emphasis on newly described patterns: implications for diagnosis on small biopsy specimens. Am. J. Clin. Pathol. 2012; 137; 229-239.
121. Hashimoto H, Daimaru Y, Enjoji M. S-100 protein distribution in liposarcoma. An immunoperoxidase study with special reference to the distinction of liposarcoma from myxoid malignant fibrous histiocytoma. Virchows Arch. A Pathol. Anat. Histopathol. 1984; 405; 1-10.
122. Tallini G, Akerman M, Dal Cin P et al. Combined morphologic and karyotypic study of 28 myxoid liposarcomas. Implications for a revised morphologic typing (a report from the CHAMP Group). Am. J. Surg. Pathol. 1996; 20; 1047-1055.
123. Knight JC, Renwick PJ, Cin PD, Van den Berghe H, Fletcher CD. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995; 55; 24-27.
124. Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. Genes Chromosom. Cancer 2007; 46; 961-971.
125. Kubo T, Matsui Y, Naka N et al. Specificity of fusion genes in adipocytic tumors. Anticancer Res. 2010; 30; 661-664.
126. Suzuki K, Matsui Y, Endo K et al. Myxoid liposarcoma with EWS-CHOP type 1 fusion gene. Anticancer Res. 2010; 30; 4679-4683.
127. Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Res. 2001; 7; 3977-3987.
128. Zvaigzne CG, Patton DJ, Kaur H, Trevenen CL, Kaura D. Subscapular tumoral calcinosis in a toddler: case report. J. Radiol. Case Rep. 2012; 6; 10-17.
129. Engstrom K, Willen H, Kabjorn-Gustafsson C et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am. J. Pathol. 2006; 168; 1642-1653.
130. Lanckohr C, Kasprzynski A, Klein-Hitpass L et al. Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation. Pathology 2010; 31; 60-66.
131. Antonescu CR, Argani P, Erlandson RA, Healey JH, Ladanyi M, Huvos AG. Skeletal and extraskeletal myxoid chondrosarcoma. A comparative clinicopathologic, ultrastructural, and molecular study. Cancer 1998; 83; 1504-1521.
132. Enzinger FM, Shiraki M. Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum. Pathol. 1972; 3; 421-435.
133. Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am. J. Surg. Pathol. 1999; 23; 636-650.
134. Kawaguchi S, Wada T, Nagoya S et al. Extraskeletal myxoid chondrosarcoma: a multi-institutional study of 42 cases in Japan. Cancer 2003; 97; 1285-1292.
135. Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum. Pathol. 2003; 34; 263-269.
136. Lucas DR, Fletcher CD, Adsay NV, Zalupski MM. High-grade extraskeletal myxoid chondrosarcoma: a high-grade epithelioid malignancy. Histopathology 1999; 35; 201-208.
137. Domanski HA, Carlen B, Mertens F, Akerman M. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a case report with fine-needle aspiration biopsy, histopathology, electron microscopy, and cytogenetics. Ultrastruct. Pathol. 2003; 27; 363-368.
138. Goh YW, Spagnolo DV, Platten M et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology 2001; 39; 514-524.
139. Okamoto S, Hisaoka M, Ishida T et al. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Hum. Pathol. 2001; 32; 1116-1124.
140. Turc-Carel C, Dal Cin P, Rao U, Karakousis C, Sandberg AA. Recurrent breakpoints at 9q31 and 22q12.2 in extraskeletal myxoid chondrosarcoma. Cancer Genet. Cytogenet. 1988; 30; 145-150.
141. Harris M, Coyne J, Tariq M et al. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a pathologic, cytogenetic, and molecular study of a case with a novel translocation t(9;17)(q22;q11.2). Am. J. Surg. Pathol. 2000; 24; 1020-1026.
142. Filion C, Motoi T, Olshen AB et al. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J. Pathol. 2009; 217; 83-93.
143. Vergara-Lluri ME, Stohr BA, Puligandla B, Brenholz P, Horvai AE. A novel sarcoma with dual differentiation: clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma. Am. J. Surg. Pathol. 2012; 36; 1093-1098.
144. Thway K, Fisher C. Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status. Am. J. Surg. Pathol. 2012; 36; e1-e11.
145. Flucke U, Mentzel T, Verdijk MA et al. EWSR1-ATF1 chimeric transcript in a myoepithelial tumor of soft tissue: a case report. Hum. Pathol. 2012; 43; 764-768.
146. Gru AA, Becker N, Pfeifer JD. Angiosarcoma of the parotid gland with a t(12;22) translocation creating a EWSR1-ATF1 fusion: a diagnostic dilemma. J Clin Pathol. 2013; 66; 452-454.
147. Enzinger FM. Angiomatoid malignant fibrous histiocytoma: a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer 1979; 44; 2147-2157.
148. Pettinato G, Manivel JC, De Rosa G, Petrella G, Jaszcz W. Angiomatoid malignant fibrous histiocytoma: cytologic, immunohistochemical, ultrastructural, and flow cytometric study of 20 cases. Mod. Pathol. 1990; 3; 479-487.
149. Fanburg-Smith JC, Miettinen M. Angiomatoid 'malignant' fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum. Pathol. 1999; 30; 1336-1343.
150. Davies KA, Cope AP, Schofield JB et al. A rare mediastinal tumour presenting with systemic effects due to IL-6 and tumour necrosis factor (TNF) production. Clin. Exp. Immunol. 1995; 99; 117-123.
151. Asakura S, Tezuka N, Inoue S, Kihara N, Fujino S. Angiomatoid fibrous histiocytoma in mediastinum. Ann. Thorac. Surg. 2001; 72; 283-285.
152. Ren L, Guo SP, Zhou XG, Chan JK. Angiomatoid fibrous histiocytoma: first report of primary pulmonary origin. Am. J. Surg. Pathol. 2009; 33; 1570-1574.
153. Moura RD, Wang X, Lonzo ML, Erickson-Johnson MR, Garcia JJ, Oliveira AM. Reticular angiomatoid 'malignant' fibrous histiocytoma-a case report with cytogenetics and molecular genetic analyses. Hum. Pathol. 2011; 42; 1359-1363.
154. Dunham C, Hussong J, Seiff M, Pfeifer J, Perry A. Primary intracerebral angiomatoid fibrous histiocytoma: report of a case with a t(12;22)(q13;q12) causing type 1 fusion of the EWS and ATF-1 genes. Am. J. Surg. Pathol. 2008; 32; 478-484.
155. Ochalski PG, Edinger JT, Horowitz MB et al. Intracranial angiomatoid fibrous histiocytoma presenting as recurrent multifocal intraparenchymal hemorrhage. J. Neurosurg. 2010; 112; 978-982.
156. Mangham DC, Williams A, Lalam RK, Brundler MA, Leahy MG, Cool WP. Angiomatoid fibrous histiocytoma of bone: a calcifying sclerosing variant mimicking osteosarcoma. Am. J. Surg. Pathol. 2010; 34; 279-285.
157. Petrey WB, LeGallo RD, Fox MG, Gaskin CM. Imaging characteristics of angiomatoid fibrous histiocytoma of bone. Skeletal Radiol. 2011; 40; 233-237.
158. Fletcher CD. Angiomatoid 'malignant fibrous histiocytoma': an immunohistochemical study indicative of myoid differentiation. Hum. Pathol. 1991; 22; 563-568.
159. Costa MA, Silva I, Carvalhido L et al. Angiomatoid fibrous histiocytoma of the arm treated by radiotherapy for local recurrence-case report. Med. Pediatr. Oncol. 1997; 28; 373-376.
160. Tornoczky T, Bogner B, Krausz T, Ottoffy G, Szuhai K. Angiomatoid fibrous histiocytoma: pleomorphic variant associated with multiplication of EWSR1-CREB1 fusion gene. Pathol. Oncol. Res. 2012; 18; 545-548.
161. Toccanier-Pelte MF, Skalli O, Kapanci Y, Gabbiani G. Characterization of stromal cells with myoid features in lymph nodes and spleen in normal and pathologic conditions. Am. J. Pathol. 1987; 129; 109-118.
162. Tanas MR, Rubin BP, Montgomery EA et al. Utility of FISH in the diagnosis of angiomatoid fibrous histiocytoma: a series of 18 cases. Mod. Pathol. 2010; 23; 93-97.
163. Hallor KH, Micci F, Meis-Kindblom JM et al. Fusion genes in angiomatoid fibrous histiocytoma. Cancer Lett. 2007; 251; 158-163.
164. Raddaoui E, Donner LR, Panagopoulos I. Fusion of the FUS and ATF1 genes in a large, deep-seated angiomatoid fibrous histiocytoma. Diagn. Mol. Pathol. 2002; 11; 157-162.
165. Thway K, Stefanaki K, Papadakis V, Fisher C. Metastatic angiomatoid fibrous histiocytoma of the scalp, with EWSR1-CREB1 gene fusions in primary tumor and nodal metastasis. Hum. Pathol. 2013; 44; 289-293.
166. Enzinger FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 1965; 18; 1163-1174.
167. Kosemehmetoglu KFA. Clear cell sarcoma of tendons and aponeuroses, and osteoclast-rich tumour of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: a review and update. J. Clin. Pathol. 2010; 63; 416-423.
168. Sara AS, Evans HL, Benjamin RS. Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer 1990; 65; 367-374.
169. Lucas DR, Nascimento AG, Sim FH. Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am. J. Surg. Pathol. 1992; 16; 1197-1204.
170. Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 30 cases. Cancer 1999; 86; 969-975.
171. Finley JW, Hanypsiak B, McGrath B, Kraybill W, Gibbs JF. Clear cell sarcoma: the Roswell Park experience. J. Surg. Oncol. 2001; 77; 16-20.
172. Dim DC, Cooley LD, Miranda RN. Clear cell sarcoma of tendons and aponeuroses: a review. Arch. Pathol. Lab. Med. 2007; 131; 152-156.
173. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N. Engl. J. Med. 2005; 353; 701-711.
174. Coindre JM, Hostein I, Terrier P et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer 2006; 107; 1055-1064.
175. Jakubauskas A, Valceckiene V, Andrekute K, Seinin D, Kanopka A, Griskevicius L. Discovery of two novel EWSR1/ATF1 transcripts in four chimerical transcripts-expressing clear cell sarcoma and their quantitative evaluation. Exp. Mol. Pathol. 2011; 90; 194-200.
176. Gineikiene E, Seinin D, Brasiuniene B, Brazaitis A, Griskevicius L, Jakubauskas A. Clear cell sarcoma expressing a novel chimerical transcript EWSR1 exon 7/ATF1 exon 6. Virchows Arch. 2012; 461; 339-343.
177. Davis IJ, Kim JJ, Ozsolak F et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006; 9; 473-484.
178. Brown AD, Lopez-Terrada D, Denny C, Lee KA. Promoters containing ATF-binding sites are de-regulated in cells that express the EWS/ATF1 oncogene. Oncogene 1995; 10; 1749-1756.
179. Fujimura Y, Ohno T, Siddique H, Lee L, Rao VN, Reddy ES. The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. Oncogene 1996; 12; 159-167.
180. Fuse N, Yasumoto K, Suzuki H, Takahashi K, Shibahara S. Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene. Biochem. Biophys. Res. Commun. 1996; 219; 702-707.
181. Tachibana M, Takeda K, Nobukuni Y et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat. Genet. 1996; 14; 50-54.
182. Amae S, Fuse N, Yasumoto K et al. Identification of a novel isoform of microphthalmia-associated transcription factor that is enriched in retinal pigment epithelium. Biochem. Biophys. Res. Commun. 1998; 247; 710-715.
183. Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan MF, Ladanyi M. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J. Mol. Diagn. 2002; 4; 44-52.
184. Li KK, Goodall J, Goding CR et al. The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma. Br. J. Cancer 2003; 89; 1072-1078.
185. Segal NH, Pavlidis P, Noble WS et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J. Clin. Oncol. 2003; 21; 1775-1781.
186. Zambrano E, Reyes-Mugica M, Franchi A, Rosai J. An osteoclast-rich tumor of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 cases of a GIST simulator. Int. J. Surg. Pathol. 2003; 11; 75-81.
187. Antonescu CR, Nafa K, Segal NHDal Cin P, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin. Cancer Res. 2006; 12; 5356-5362.
188. Huang W, Zhang X, Li D et al. Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts. Virchows Arch. 2006; 448; 200-203.
189. Stockman DL, Miettinen M, Suster S et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am. J. Surg. Pathol. 2012; 36; 857-868.
190. Taminelli L, Zaman K, Gengler C et al. Primary clear cell sarcoma of the ileum: an uncommon and misleading site. Virchows Arch. 2005; 447; 772-777.
191. Covinsky M, Gong S, Rajaram V, Perry A, Pfeifer J. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma. Hum. Pathol. 2005; 36; 74-81.
192. Ekfors TO, Kujari H, Isomaki M. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) in the duodenum: the first visceral case. Histopathology 1993; 22; 255-259.
193. Pauwels P, Debiec-Rychter M, Sciot R et al. Clear cell sarcoma of the stomach. Histopathology 2002; 41; 526-530.
194. Abdulkader I, Cameselle-Teijeiro J, de Alava E, Ruiz-Ponte C, Used-Aznar MM, Forteza J. Intestinal clear cell sarcoma with melanocytic differentiation and EWS [corrected] rearrangement: report of a case. Int. J. Surg. Pathol. 2008; 16; 189-193.
195. Nicholson AG, Baandrup U, Florio R, Sheppard MN, Fisher C. Malignant myxoid endobronchial tumour: a report of two cases with a unique histological pattern. Histopathology 1999; 35; 313-318.
196. Kilpatrick SE, Hitchcock MG, Kraus MD, Calonje E, Fletcher CDM. Mixed tumors and myoepitheliomas of soft tissue-a clinicopathologic study of 19 cases with a unifying concept. Am. J. Surg. Pathol. 1997; 21; 13-22.
197. Venkatraman L, Sinnathuray AR, Raut V, Brooker DS, McCluggage WG. Soft tissue myoepithelioma: a case report. Pathology 2002; 34; 451-454.
198. Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am. J. Surg. Pathol. 2003; 27; 1183-1196.
199. Neto AG, Pineda-Daboin K, Luna MA. Myoepithelioma of the soft tissue of the head and neck: a case report and review of the literature. Head Neck 2004; 26; 470-473.
200. Lee JR, Georgi DE, Wang BY. Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature. Ann. Diagn. Pathol. 2007; 11; 190-198.
201. Nikitakis NG, Argyris P, Sklavounou A, Papadimitriou JC. Oral myoepithelioma of soft tissue origin: report of a new case and literature review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010; 110; e48-e51.
202. Burke T, Sahin A, Johnson DE, Ordonez NG, Mackay B. Myoepithelioma of the retroperitoneum. Ultrastruct. Pathol. 1995; 19(269-27); 4.
203. Cibull TL, Gleason BC, O'Malley DP, Billings SD, Wiersema P, Hiatt KM. Malignant cutaneous glomus tumor presenting as a rapidly growing leg mass in a pregnant woman. J. Cutan. Pathol. 2008; 35; 765-769.
204. Stout AP, Gorman JG. Mixed tumors of the skin of the salivary gland type. Cancer 1959; 12; 537-543.
205. Fernandez-Figueras M-T, Puig L, Trias I, Lorenzo J-C, Navas-Palacios J-J. Benign myoepithelioma of the skin. Am. J. Dermatopathol. 1998; 20; 208-212.
206. Kutzner H, Mentzel T, Kaddu S, Soares LM, Sangueza OP, Requena L. Cutaneous myoepithelioma: an under-recognized cutaneous neoplasm composed of myoepithelial cells. Am. J. Surg. Pathol. 2001; 25; 348-355.
207. Michal M, Miettinen M. Myoepitheliomas of the skin and soft tissues. Report of 12 cases. Virchows Arch. 1999; 434; 393-400.
208. Ammerlaan AC, Ararou A, Houben MP et al. Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br. J. Cancer 2008; 98; 474-479.
209. Hornick JLDal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am. J. Surg. Pathol. 2009; 33; 542-550.
210. Kurzawa P, Kattapuram S, Hornicek FJ, Antonescu CR, Rosenberg AE, Nielsen GP. Primary myoepithelioma of bone: a report of 8 cases. Am. J. Surg. Pathol. 2013; 37; 960-968.
211. Brandal P, Panagopoulos I, Bjerkehagen B et al. Detection of a t(1;22)(q23;q12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma. Genes Chromosom. Cancer 2008; 47; 558-564.
212. Brandal P, Panagopoulos I, Bjerkehagen B, Heim S. t(19;22)(q13;q12) Translocation leading to the novel fusion gene EWSR1-ZNF444 in soft tissue myoepithelial carcinoma. Genes Chromosom. Cancer 2009; 48; 1051-1056.
213. Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am. J. Surg. Pathol. 2003; 27; 421-431.
214. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010; 456; 219-234.